Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in epstein-barr virus reactivation from Latency

Journal of Virology

Volumn 87, Issue 18, 2013, Pages 10148-10162

  Murata, Takayuki ^a,b   Narita, Yohei ^a   Sugimoto, Atsuko ^a   Kawashima, Daisuke ^a   Kanda, Teru ^a   Tsurumi, Tatsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B ZIP FAMILY TRANSCRIPTION FACTOR; HISTONE; IMMEDIATE EARLY PROTEIN BZLF1; KRUPPEL LIKE FACTOR 4; MYOCYTE ENHANCER FACTOR 2B FAMILY TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; B LYMPHOCYTE; BALF5 GENE; BINDING SITE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPSTEIN BARR VIRUS; GENE ISOLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; LATENT PERIOD; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; VIRUS GENE; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION;

CELL LINE; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MYOGENIC REGULATORY FACTORS; TRANS-ACTIVATORS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84883276335     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01002-13     Document Type: Article

References (56)

1. Tsurumi T, Fujita M, Kudoh A. 2005. Latent and lytic Epstein-Barr virus replication strategies. Rev. Med. Virol. 15:3-15.
2. Amon W, Farrell PJ. 2005. Reactivation of Epstein-Barr virus from latency. Rev. Med. Virol. 15:149-156.
3. Speck SH, Chatila T, Flemington E. 1997. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol. 5:399-405.
4. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. 2007. Lytic cycle switches of oncogenic human gammaherpesviruses. Adv. Cancer Res. 97:81-109.
5. Sinclair AJ. 2003. bZIP proteins of human gammaherpesviruses. J. Gen. Virol. 84:1941-1949.
6. Liu S, Liu P, Borras A, Chatila T, Speck SH. 1997. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J. 16:143-153.
7. Liu S, Borras AM, Liu P, Suske G, Speck SH. 1997. Binding of the ubiquitous cellular transcription factors Sp1 and Sp3 to the ZI domains in the Epstein-Barr virus lytic switch BZLF1 gene promoter. Virology 228: 11-18.
8. Murata T, Noda C, Saito S, Kawashima D, Sugimoto A, Isomura H, Kanda T, Yokoyama KK, Tsurumi T. 2011. Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency. J. Biol. Chem. 286:22007-22016.
9. Murata T, Sato Y, Nakayama S, Kudoh A, Iwahori S, Isomura H, Tajima M, Hishiki T, Ohshima T, Hijikata M, Shimotohno K, Tsurumi T. 2009. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein. J. Biol. Chem. 284:8033-8041.
10. Ruf IK, Rawlins DR. 1995. Identification and characterization of ZIIBC, a complex formed by cellular factors and the ZII site of the Epstein-Barr virus BZLF1 promoter. J. Virol. 69:7648-7657.
11. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. 2007. X-boxbinding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J. Virol. 81:7363-7370.
12. McDonald C, Karstegl CE, Kellam P, Farrell PJ. 2010. Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency. J. Gen. Virol. 91:622-629.
13. Sun CC, Thorley-Lawson DA. 2007. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J. Virol. 81:13566-13577.
14. Flemington E, Speck SH. 1990. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1227-1232.
15. Murata T, Hotta N, Toyama S, Nakayama S, Chiba S, Isomura H, Ohshima T, Kanda T, Tsurumi T. 2010. Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase. J. Biol. Chem. 285:23925-23935.
16. Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S, Isomura H,Kanda T, Tsurumi T. 2012. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J. Virol. 86:4752-4761.
17. Yu X, Wang Z, Mertz JE. 2007. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog. 3:e194. doi:10.1371/journal .ppat.0030194.
18. Montalvo EA, Cottam M, Hill S, Wang YJ. 1995. YY1 binds to and regulates cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter. J. Virol. 69:4158-4165.
19. Hagemeier SR, Dickerson SJ, Meng Q, Yu X, Mertz JE, Kenney SC. 2010. Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase. J. Virol. 84:4383-4394.
20. Gruffat H, Manet E, Rigolet A, Sergeant A. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18:6835-6843.
21. Ragoczy T, Miller G. 2001. Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J. Virol. 75:5240-5251.
22. Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J, Kenney S. 2000. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74: 1224-1233.
23. Manet E, Gruffat H, Trescol-Biemont MC, Moreno N, Chambard P, Giot JF, Sergeant A. 1989. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J. 8:1819-1826.
24. Murata T, Isomura H, Yamashita Y, Toyama S, Sato Y, Nakayama S, Kudoh A, Iwahori S, Kanda T, Tsurumi T. 2009. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. Virology 389:75-81.
25. Hagen G, Muller S, Beato M, Suske G. 1994. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J. 13:3843-3851.
26. Ego T, Tanaka Y, Shimotohno K. 2005. Interaction of HTLV-1 Tax and methyl-CpG-binding domain 2 positively regulates the gene expression from the hypermethylated LTR. Oncogene 24:1914-1923.
27. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250.
28. Noda C, Murata T, Kanda T, Yoshiyama H, Sugimoto A, Kawashima D, Saito S, Isomura H, Tsurumi T. 2011. Identification and characterization of CCAAT enhancer-binding protein (C/EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent membrane protein 1. J. Biol. Chem. 286:42524-42533.
29. Flemington E, Speck SH. 1990. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217-1226.
30. Taylor N, Flemington E, Kolman JL, Baumann RP, Speck SH, Miller G. 1991. ZEBRA and a Fos-GCN4 chimeric protein differ in their DNAbinding specificities for sites in the Epstein-Barr virus BZLF1 promoter. J. Virol. 65:4033-4041.
31. Kaczynski J, Cook T, Urrutia R. 2003. Sp1-and Kruppel-like transcription factors. Genome Biol. 4:206.
32. Potthoff MJ, Olson EN. 2007. MEF2: a central regulator of diverse developmental programs. Development 134:4131-4140.
33. Katoh Y, Molkentin JD, Dave V, Olson EN, Periasamy M. 1998. MEF2B is a component of a smooth muscle-specific complex that binds an A/Trich element important for smooth muscle myosin heavy chain gene expression. J. Biol. Chem. 273:1511-1518.
34. Molkentin JD, Firulli AB, Black BL, Martin JF, Hustad CM, Copeland N, Jenkins N, Lyons G, Olson EN. 1996. MEF2B is a potent transactivator expressed in early myogenic lineages. Mol. Cell. Biol. 16:3814-3824.
35. Bryant H, Farrell PJ. 2002. Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J. Virol. 76:10290-10298.
36. Isomura H, Stinski MF, Kudoh A, Daikoku T, Shirata N, Tsurumi T. 2005. Two Sp1/Sp3 binding sites in the major immediate-early proximal enhancer of human cytomegalovirus have a significant role in viral replication. J. Virol. 79:9597-9607.
37. Lang D, Fickenscher H, Stamminger T. 1992. Analysis of proteins binding to the proximal promoter region of the human cytomegalovirus IE-1/2 enhancer/promoter reveals both consensus and aberrant recognition sequences for transcription factors Sp1 and CREB. Nucleic Acids Res. 20: 3287-3295.
38. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
39. Lu CC, Jeng YY, Tsai CH, Liu MY, Yeh SW, Hsu TY, Chen MR. 2006. Genome-wide transcription program and expression of the Rta responsive gene of Epstein-Barr virus. Virology 345:358-372.
40. Ragoczy T, Miller G. 1999. Role of the Epstein-Barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J. Virol. 73:9858-9866.
41. Heilmann AM, Calderwood MA, Portal D, Lu Y, Johannsen E. 2012. Genome-wide analysis of Epstein-Barr virus Rta DNA binding. J. Virol. 86:5151-5164.
42. Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M. 2009. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 19:438-451.
43. Li L, Su X, Choi GC, Cao Y, Ambinder RF, Tao Q. 2012. Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK-and B-cell origins. BMC Cancer 12:125.
44. Woellmer A, Arteaga-Salas JM, Hammerschmidt W. 2012. BZLF1 governs CpG-methylated chromatin of Epstein-Barr virus reversing epigenetic repression. PLoS Pathog. 8:e1002902. doi:10.1371/journal.ppat .1002902.
45. Gruffat H, Manet E, Sergeant A. 2002. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 3:141-146.
46. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. 2004. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat. Genet. 36:1099-1104.
47. Ramasubramanyan S, Osborn K, Flower K, Sinclair AJ. 2012. Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome. J. Virol. 86:1809-1819.
48. Arvey A, Tempera I, Tsai K, Chen HS, Tikhmyanova N, Klichinsky M, Leslie C, Lieberman PM. 2012. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12:233-245.
49. Chen HS, Wikramasinghe P, Showe L, Lieberman PM. 2012. Cohesins repress Kaposi's sarcoma-associated herpesvirus immediate early gene transcription during latency. J. Virol. 86:9454-9464.
50. Swanson BJ, Jack HM, Lyons GE. 1998. Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. Mol. Immunol. 35: 445-458.
51. Jiang JH, Wang N, Li A, Liao WT, Pan ZG, Mai SJ, Li DJ, Zeng MS, Wen JM, Zeng YX. 2006. Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. J. Clin. Virol. 37:98-103.
52. Stinski MF, Isomura H. 2008. Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med. Microbiol. Immunol. 197:223-231.
53. Wysocka J, Herr W. 2003. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem. Sci. 28:294-304.
54. Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV. 2009. Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog. 5:e1000260. doi:10.1371/journal.ppat.1000260.
55. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. 2003. NFkappaB inhibits gammaherpesvirus lytic replication. J. Virol. 77:8532-8540.
56. Saito S, Murata T, Kanda T, Isomura H, Narita Y, Sugimoto A, Kawashima D, Tsurumi T. 2013. Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-kappaB signaling during productive replication. J. Virol. 87:4060-4070.